BioInnovatise Launches New AAV Packaging Service for Biotechnology and Biopharmaceutical Research and Development

BioInnovatise Launches New AAV Packaging Service for Accelerating Research and Development

December 11, 2024

Rockville, MD — BioInnovatise is excited to unveil its cutting-edge AAV Packaging Service, strategically designed to amplify the potential of early-stage research and development and provide services for the largest viral vector used in research today. Demonstrating an unwavering commitment to scientific advancement, BioInnovatise delivers fast, reliable, and high-precision contract development and manufacturing organization (CDMO) services for viral vector based research, with a specialized focus on plasmid DNA services and viral vector packaging.

With over 30,000 cloning constructs produced, 100+ lentiviral vectors packaged, and more than 1,000 plasmid DNA preparations, BioInnovatise is prepared to meet your viral vector, including AAV packaging, adenovirus packaging, lentivirus packaging, and retrovirus packaging, needs efficiently. Our quick turnaround times ensure that projects proceed without unnecessary delays.

The introduction of our new AAV packaging service strategically enhances our existing portfolio of adenovirus, retrovirus and lentivirus offerings, providing researchers with an comprehensive and integrated range of viral vectors for early discovery phase R&D. These synergistic services empower researchers with flexible, precision engineered solutions that address the multifaceted demands of gene therapy, immunology, and oncology research, thereby accelerating the pathway to transformative scientific breakthroughs.

Quick Turnaround AAV Packaging for Research and Development

If you are uncertain about which packaging service is best for your research, our viral vector team is available to assist you. Our research grade viral vector services include:

• Crude (for in vitro): ~10E11 GC/ml | Available in 250 μl, 500 μl, and 1 ml volumes.
• Ultracentrifugation purified (for in vitro or in vivo): ~10E13 GC/ml l | Available in 250 μl, 500 μl, and 1 ml volumes.

Our viral vector team employs a validated assay to determine viral titer in all AAV productions through RT-qPCR, using primers designed to amplify conserved internal sequences in the adeno-associated genome.

AAV Packaging Production Options

• Cell Lines: AAV transductions are performed using a HEK293T cell line (Human Embryonic Kidney 293 Transient) to ensure high transfection efficiency.
• Serotype selection: Our facility can produce adeno-associated virus packaging productions to match your research needs including serotypes: AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ, AAVrh10, and Anc80.
• Transfection Protocol: AAV packaging is produced according to client specifications. If you lack a adenovirus transfection protocol, we can assist in developing one suited to your research needs.
• Quality Control: All adenovirus productions have titer levels measured with a RT-qPCR assay. Additional quality control tests are available upon request, including ELISA, infectious titer assay, SDS-PAGE / Western blot, Transmission Electron Microscopy, Analytical Ultracentrifugation, sterility test / endotoxin assay

About BioInnovatise

BioInnovatise is a leading CDMO specializing in high-quality support for plasmid DNA and viral vector research. Our services are designed to deliver efficient and reliable solutions for advancements in cell and gene therapy, immunotherapy, precision medicine, and more.